{"id":514100,"date":"2026-06-27T18:36:11","date_gmt":"2026-06-27T18:36:11","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/514100\/"},"modified":"2026-06-27T18:36:11","modified_gmt":"2026-06-27T18:36:11","slug":"humacyte-huma-stock-fair-value-falls-as-split-analyst-views-follow-v012-data","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/514100\/","title":{"rendered":"Humacyte (HUMA) Stock Fair Value Falls As Split Analyst Views Follow V012 Data"},"content":{"rendered":"\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><a href=\"https:\/\/simplywall.st\/discover\/investing-ideas?utm_medium=finance_user&amp;utm_campaign=investing_ideas_head_cta&amp;utm_source=yahoo&amp;blueprint=4640060\" data-ylk=\"slk:Find%20winning%20stocks;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkText&quot;:&quot;Find winning stocks&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Find winning stocks<\/a> in any market cycle. Join 7 million investors using Simply Wall St&#8217;s investing ideas for FREE.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Humacyte&#8217;s fair value estimate has been reset from US$7.86 to US$2.05, marking a sharp recalibration of how analysts are framing the stock&#8217;s potential. Recent research highlights a split view, with some analysts leaning into the acellular vessel opportunity after the V012 data and others trimming expectations, which together help explain the lower fair value target. As you read on, you will see what is driving this evolving Humacyte narrative and how to keep track of the next key inflection points.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Stay updated as the Fair Value for <a href=\"https:\/\/www.simplywall.st\/\/company\/id\/ff0a95ff-7238-4a18-bc47-781bfc9790d2\/valuation?utm_medium=finance_user&amp;utm_campaign=stay_updated_cta&amp;utm_source=yahoo\" data-ylk=\"slk:Humacyte;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkText&quot;:&quot;Humacyte&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Humacyte<\/a> shifts by adding it to your <a href=\"https:\/\/simplywall.st\/features\/stock-watchlist?utm_medium=finance_user&amp;utm_campaign=stay_updated_cta&amp;utm_source=yahoo&amp;blueprint=4640060\" data-ylk=\"slk:watchlist;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkText&quot;:&quot;watchlist&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">watchlist<\/a> or <a href=\"https:\/\/simplywall.st\/features\/portfolio?utm_medium=finance_user&amp;utm_campaign=stay_updated_cta&amp;utm_source=yahoo&amp;blueprint=4640060\" data-ylk=\"slk:portfolio;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkText&quot;:&quot;portfolio&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">portfolio<\/a>. Alternatively, explore our <a href=\"https:\/\/simplywall.st\/stock\/NasdaqGS\/HUMA?utm_medium=finance_user&amp;utm_campaign=stay_updated_cta&amp;utm_source=yahoo&amp;blueprint=4640060\" data-ylk=\"slk:Community;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkText&quot;:&quot;Community&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Community<\/a> to discover new perspectives on Humacyte.  <\/p>\n<p>        What Wall Street Has Been Saying          \ud83d\udc02 Bullish Takeaways            <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Several firms point to Humacyte&#8217;s V012 interim data as a key support for the story, with TD Cowen and H.C. Wainwright highlighting that the study met its primary endpoint and showed positive secondary analyses.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">H.C. Wainwright lifted its price target to US$4 from US$3 after the V012 update, citing expectations around a dialysis indication and a view that the acellular vessel platform can support future revenue over time.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Benchmark raised its target to US$2 from US$1 after discussions with management, reflecting updated assumptions for Symvess and the acellular tissue engineered vessel AV graft in its model.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">TD Cowen previously raised its target to US$1.50 from US$1, pointing to Symvess and potential indication expansion in AV access, CABG and PAD, which it sees as larger market opportunities.  <\/p>\n<p>              \ud83d\udc3b Bearish Takeaways            <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">More recently, TD Cowen reduced its target to US$1.25 from US$1.50, despite a positive view on the V012 data, suggesting increased caution on execution, timelines or valuation assumptions around Humacyte.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Mentions of lower targets and a downgrade at firms like Barclays, Piper Sandler and Benchmark signal that some analysts are more guarded on risk, even as they continue to track the same clinical and regulatory milestones.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there&#8217;s more to the story. <a href=\"https:\/\/simplywall.st\/features\/community-narratives?utm_medium=finance_user&amp;utm_campaign=cta_community_contributor&amp;utm_source=yahoo&amp;blueprint=4640060\" data-ylk=\"slk:Head%20to%20the%20Simply%20Wall%20St%20Community%20to%20discover%20more%20perspectives!;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkText&quot;:&quot;Head to the Simply Wall St Community to discover more perspectives!&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Head to the Simply Wall St Community to discover more perspectives!<\/a>  <\/p>\n<p>    <a href=\"https:\/\/www.simplywall.st\/\/company\/id\/ff0a95ff-7238-4a18-bc47-781bfc9790d2?utm_medium=finance_user&amp;utm_campaign=infographic&amp;utm_source=yahoo\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"NasdaqGS:HUMA 1-Year Stock Price Chart\" height=\"664\" width=\"960\" class=\"yf-lglytj loader\"\/><\/a> NasdaqGS:HUMA 1-Year Stock Price Chart           <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><a href=\"https:\/\/www.simplywall.st\/company\/id\/ff0a95ff-7238-4a18-bc47-781bfc9790d2?utm_medium=finance_user&amp;utm_campaign=cta_news_risk_alert&amp;utm_source=yahoo\" data-ylk=\"slk:We&#039;ve%20flagged%203%20risks%20for%20Humacyte.%20See%20which%20could%20impact%20your%20investment.;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkText&quot;:&quot;We&#039;ve flagged 3 risks for Humacyte. See which could impact your investment.&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">We&#8217;ve flagged 3 risks for Humacyte. See which could impact your investment.<\/a>  <\/p>\n<p>        How This Changes the Fair Value For Humacyte             <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Fair value reset from US$7.86 to US$2.05, reflecting materially revised assumptions for Humacyte&#8217;s outlook.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Long term revenue growth assumption moved from 463% to 313%.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Long term net profit margin outlook reduced from 36.85% to 0.34%.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Future P\/E multiple assumption changed from 21.60x to 1,434.48x.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Discount rate adjusted from 7.43% to 8.01%.  <\/p>\n<p>    Story Continues  <\/p>\n<p>           Never Miss an Update: Follow The Narrative         <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Narratives connect Humacyte&#8217;s clinical story and commercial roll out to a structured financial forecast and fair value range. They update automatically as new trial data, regulatory milestones and capital raises come through, so you can see how the story is evolving in real time.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Head over to the Simply Wall St Community and <a href=\"https:\/\/simplywall.st\/narratives\/84goxvcw-update-for-humacyte?blueprint=4640060&amp;utm_source=yahoo&amp;utm_medium=finance_user&amp;utm_campaign=integrated-pitch\" data-ylk=\"slk:follow%20the%20Narrative%20on%20Humacyte;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkText&quot;:&quot;follow the Narrative on Humacyte&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">follow the Narrative on Humacyte<\/a> to stay up to date on:  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">How Symvess use in trauma and hospital acquired vascular complications, plus ECAT and VA access, could shape surgeon adoption and institutional demand.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">What the V012 dialysis trial and potential label expansion around 2027 might mean for recurring procedure volumes and the broader acellular vessel platform.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Key execution risks, including pricing pressure, early stage commercialization, cash burn, and uncertainty around longer dated CABG and tubular organ programs.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Companies discussed in this article include <a href=\"https:\/\/finance.yahoo.com\/quote\/HUMA\" data-ylk=\"slk:HUMA;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkText&quot;:&quot;HUMA&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;}\" target=\"_blank\" rel=\"nofollow noopener\">HUMA<\/a>.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Have feedback on this article? Concerned about the content? <a href=\"https:\/\/investor-research.typeform.com\/to\/wvg6MFri#feedback_token=NDY0MDA2MDowNWM4OTg3ZDU2MzYzMzEx&amp;company=NasdaqGS:HUMA&amp;blueprintid=4640060\" data-ylk=\"slk:Get%20in%20touch;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkText&quot;:&quot;Get in touch&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Get in touch<\/a> with us directly. Alternatively, email <a href=\"https:\/\/finance.yahoo.com\/markets\/stocks\/articles\/mailto:editorial-team@simplywallst.com?subject=Re%3A%20Your%20article%20on%20NasdaqGS%3AHUMA%20(yahoo)%20from%2027th%20June%202026\" data-ylk=\"slk:editorial-team%40simplywallst.com;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkText&quot;:&quot;editorial-team@simplywallst.com&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">editorial-team@simplywallst.com<\/a>  <\/p>\n","protected":false},"excerpt":{"rendered":"Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St&#8217;s investing ideas for&hellip;\n","protected":false},"author":2,"featured_media":514101,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[114,11628,235702,85,46],"class_list":["post-514100","post","type-post","status-publish","format-standard","has-post-thumbnail","category-business","tag-business","tag-fair-value","tag-humacyte","tag-il","tag-israel"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/514100","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=514100"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/514100\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/514101"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=514100"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=514100"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=514100"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}